| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.02 | 1.77% | 14.36万 | 5701.54万 | | 920982 | 锦波生物 | 234.00 | 0.02% | 7738.5 | 1.83 Z | | 688363 | 华熙生物 | 49.78 | -0.04% | 1.73万 | 8615.02万 | | 300896 | 爱美客 | 149.16 | -1.87% | 3.09万 | 4.65亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出4664.53万元，游资资金净流入1224.74万元，散户 资金净流入3439.79万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月7日医疗美容板块较上一交易日下跌0.93%，爱美客领跌。当日上证指数报收于 3997.56，下跌0.25%。深证成指报收于13404.06，下跌0.36%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | - ...

今年以来，医药板块备受投资者关注，其中创新药赛道表现尤为亮眼。当前，我国创新药管线、临床试验项目数量均位居世界前列。同时， 政策持续加 码创新药，多地也相继出台专项措施，推动产业高质量发展。国元证券认为，目前我国创新药进入成果兑现阶段，研发进展催化较多，有望持续成为2025 年医药板块投资主线。 【导读】中证科创创业创新药指数、中证科创创业医疗器械指数即将发布 其中，中证科创创业创新药指数从科创板和创业板中选取业务涉及创新药研发以及为制药企业提供药物研究、开发和生产等服务的上市公司证券作为指数 样本，以反映科创板和创业板创新药领域上市公司证券的整体表现。百济神州-U、百利天恒、康龙化成、智飞生物等50只成份股被纳入。 11月6日，中证指数有限公司发布消息称，将于11月7日正式发布中证科创创业创新药指数和中证科创创业医疗器械指数，为市场提供更丰富的投资标的。 中证科创创业医疗器械指数从科创板和创业板中选取提供医疗设备、医疗耗材和体外诊断等产品和服务的上市公司证券作为指数样本，以反映科创板和创 业板医疗器械领域上市公司证券的整体表现。迈瑞医疗、联影医疗、新产业、爱美客等50只成份股被纳入。 医疗器械方面，中泰证券 ...

从资金流向上来看，当日医疗美容板块主力资金净流出3496.21万元，游资资金净流出165.84万元，散户 资金净流入3662.05万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 533.05万 | 10.03% | -352.39万 | -6.63% | -180.67万 | -3.40% | | 688363 华熙生物 | -1236.16万 | -10.93% | 261.68万 | 2.31% | 974.49万 | 8.61% | | 300896 爱美客 | -2793.10万 | -5.87% | -75.13万 | -0.16% | 2868.22万 | 6.03% | 证券之星消息，11月6日医疗美容板块较上一交易日上涨0.18%，*ST美谷领涨。当日上证指数报收于 4007.76，上涨0.97%。深证成指报收于13452.42，上涨1.73%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | ...

证券日报网讯爱美客（300896）11月5日在互动平台回答投资者提问时表示，公司产品的终端价格受下 游渠道竞争、消费者需求等多重因素影响。2025年1-9月公司产品综合毛利率为93.36%，去年同期综合 毛利率为94.80%，公司出厂价格保持相对稳定。 ...

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][32]. Core Insights - The report highlights the recent tax policy changes regarding gold, which exempts value-added tax for standard gold transactions, potentially boosting market activity [3][22]. - The beauty care sector shows mixed performance, with some companies reporting significant revenue growth while others face declines [4][25]. - The report emphasizes the importance of domestic brands in the beauty market, with notable rankings in the Douyin beauty list indicating a shift towards local products [22][23]. Market Performance - During the week of October 27 to October 31, 2025, the retail trade, social services, and beauty care sectors experienced changes of +1.63%, +0.45%, and -2.21% respectively, ranking 8th, 17th, and 30th among 31 primary industries [13][15]. - The cosmetics sector faced a decline of -2.57%, while segments like trade and e-commerce performed well with increases of +3.44% and +2.97% [15][18]. Key Company Announcements - Shanghai Jahwa reported a revenue of 4.961 billion yuan for the first three quarters of 2025, a year-on-year increase of 10.8%, with a net profit growth of 149.1% [25]. - Proya Cosmetics achieved a revenue of 7.098 billion yuan, reflecting a modest growth of 1.89% [25]. - The opening of Pop Mart's first store in the Middle East marks a significant expansion for the brand [29]. Investment Recommendations - The report suggests focusing on companies such as Shiseido, Giant Bio, Marubi, Runben, Proya, Chaohongji, and Furuida as potential investment targets within the recommended sectors [5][32].

Group 1 - The medical beauty sector experienced a decline of 2.68% on November 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.74 (+0.27%), Huaxi Biological at 52.05 (-2.01%), Aimeike at 151.92 (-3.46%), and Jinbo Biological at 243.02 (-4.84%) [1] Group 2 - The medical beauty sector saw a net outflow of 101 million yuan from institutional investors, while retail investors had a net inflow of 79.55 million yuan [1] - The trading volume and turnover for key stocks included *ST Meigu with 140,600 shares traded and a turnover of 53.3 million yuan, Huaxi Biological with 29,200 shares and 153 million yuan, Aimeike with 43,500 shares and 669 million yuan, and Jinbo Biological with 15,400 shares and 378 million yuan [1]

每经AI快讯，有投资者在投资者互动平台提问：请问公司目前肉毒素项目审批的进度如何，何时能够 上市产生收益，另外公司今年三季度利润下滑40%，请问各项新品的研发工作是否在有序推进当中，后 续能否扭转下滑实现增长？ 爱美客（300896.SZ）11月4日在投资者互动平台表示，公司肉毒毒素项目目前在排队待审评阶段，注册 审评时间及结果需以国家药监局审评审批结果为准。公司在研项目目前在正常推进中。 （文章来源：每日经济新闻） ...

Core Insights - The performance of the new consumption sector shows significant divergence, with companies like Pop Mart achieving impressive growth, while the capital market reacts with valuation adjustments [1] - The pet economy continues to attract capital attention, with companies like Zhongchong and Guai Bao Pet reporting steady growth, yet facing valuation declines [1] - The beauty economy, represented by companies like Aimeike and Huaxi Biological, is experiencing notable declines in performance [1] IP Economy Performance - Pop Mart reported a substantial revenue increase of 245%-250% year-on-year for Q3 2025, continuing its high growth trend from the first half of the year [2] - In the Chinese market, revenue grew by 185%-190%, with online channels surging by 300%-305% and offline channels by 130%-135% [2] - Overseas revenue skyrocketed by 365%-370%, with the Americas showing an extraordinary growth of 1265%-1270% [2] - Light Media also saw significant growth, with Q3 revenue reaching 3.616 billion yuan, a 150.81% increase, and net profit soaring by 406.78% [2][3] Pet Economy Trends - Zhongchong reported Q3 revenue of 3.860 billion yuan, up 21.05%, and net profit of 333 million yuan, up 18.21% [4] - Guai Bao Pet achieved Q3 revenue of 4.737 billion yuan, a 29.03% increase, with net profit growing by 9.05% [4] - Despite high market demand, the pet economy faces challenges from homogenization and increased competition [5] Beauty Economy Challenges - Aimeike's Q3 revenue fell by 21.49% to 1.865 billion yuan, with net profit down 31.05% [6] - Huaxi Biological reported a revenue decline of 18.36% to 3.163 billion yuan, with net profit decreasing by 30.29% [6] - Beitaini's revenue dropped by 13.78% to 3.464 billion yuan, with net profit down 34.45% [6] - The medical beauty industry is undergoing a strategic transformation, with a focus on high-end markets and new materials gaining attention [6][7]

证券之星消息，11月3日医疗美容板块较上一交易日下跌1.4%，爱美客领跌。当日上证指数报收于 3976.52，上涨0.55%。深证成指报收于13404.06，上涨0.19%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流入277.89万元，游资资金净流入3054.67万元，散户 资金净流出3332.56万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.73 | 4.19% | 15.00万 | 555.89万 | | 920982 | 锦波生物 | 255.37 | 1.63% | 1.57万 | 4.03亿 | | 688363 | 华熙生物 | 53.12 | -1.61% | 2.94万 | 1.56亿 | | 300896 | 爱美客 | 157.37 | -1.70% | 3.34万 | 5.271Z | | 代码 | | | 名称 │主力净流入（元）│主力净占比│游资净流入（元） ...

October 28, 2025 12:59 PM GMT Imeik Technology Development Co Ltd | Asia Pacific M Update 3Q25 Below MSe amid Persistent Industry-wide Pressures Reaction to earnings Unchanged Meaningful shortfall Modest revision lower Impact to our thesis Financial results versus consensus Direction of next 12-month consensus EPS Source: Company data, Morgan Stanley Research Key Takeaways Morgan Stanley Asia Limited+ Alexis Yan, CFA Equity Analyst Alexis.Yan@morganstanley.com +852 2239-7953 Morgan Stanley appreciates your ...